We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImage Scan Holdings Regulatory News (IGE)

Share Price Information for Image Scan Holdings (IGE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.20
Bid: 1.10
Ask: 1.30
Change: 0.00 (0.00%)
Spread: 0.20 (18.182%)
Open: 1.20
High: 1.20
Low: 1.20
Prev. Close: 1.20
IGE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Preliminary Results 2018

5 Dec 2018 07:00

RNS Number : 4474J
Image Scan Holdings PLC
05 December 2018
 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

IMAGE SCAN HOLDINGS PLC

 

("Image Scan" or the "Company")

 

PRELIMINARY RESULTS FOR THE YEAR ENDED 30 SEPTEMBER 2018

 

Image Scan (AIM: IGE), the specialist supplier of X-ray screening systems to the security and industrial inspection markets, today announces preliminary results for the year ended 30 September 2018.

HIGHLIGHTS

· Sales of £3.5m (2017: £5m)

· Gross margin increased to 47% (2017: 38%)

· Profit before tax and exceptional costs associated with aborted acquisition of £96k (2017: £480k)

· £780k of cash at the year end (2017: £1.3m)

· Record sales of industrial inspections systems

· Launch of ThreatScan® 2 precision detectors

· Strengthened operations and sales teams

· Re-certificated Quality system to ISO 9001:2015

 

Bill Mawer, Chairman and Chief Executive of Image Scan, commented: "Image Scan grew rapidly in both sales and profits between 2015 and 2017 and so the cancelled order and the failure of the attempted acquisition have come as disappointments. A decline in portable X-ray orders has exacerbated this. Our order pipeline is strong, we have strengthened our team and re-focussed our research and development activity to drive the business forward through organic growth.

In FY19 we plan to expand our security product range, extend our geographical market reach, and further build on our recent operational improvements. Our industrial activity is performing well and continued tightening of automotive emissions legislation around the world provides a helpful backdrop for the highly specialised inspection systems we provide.

The company has attractive and highly differentiated products in strongly performing market segments. We are well placed to put the setbacks of 2018 behind us and return to the growth of previous years."

-END-

Image Scan Holdings plc Tel: +44 (0) 1509 817400

William Mawer, Chairman

Sarah Atwell-King, Company Secretary

 

 

Cantor Fitzgerald Europe Tel: +44 (0) 207 894 7000

Rick Thompson / Will Goode (Corporate Finance)

Caspar Shand Kydd (Sales)

About Image Scan Holdings plc

Image Scan Holdings plc (AIM: IGE) is focused on the development and commercialisation of market leading real-time X-ray solutions for use in the global Security and Industrial inspection markets. The Company's Security portfolio includes the ThreatScan® range of portable bomb and suspect package detection systems; the Axis range of baggage inspection systems; and SVXi, a small vehicle inspection system. The Industrial inspection solutions include the MDXi product range, cabinet X-ray systems for laboratories and production lines. The Company was founded in 1996 and joined AIM in 2002.

For further information on the Company, please visit: www.ish.co.uk - and for further information on its products, please visit: www.3dx-ray.com

CHAIRMANS STATEMENT

OVERVIEW

The results for Image Scan Holdings plc for the year ended 30 September 2018 reflected the twin setbacks faced by the business during the year. The first of these was the cancellation of a large order from an important Asian customer, reported in February; the second was the failure to garner support from the Company's largest shareholder for the intended acquisition of the security X-ray company Todd Research Limited. The first of these contributed to adverse sales performance, the second added exceptional legal and other costs to the bottom line. The impact of these setbacks was partially offset by strong performance in the industrial range, where a record number of inspection systems were delivered. The Group has a strong product range and an excellent route to its major markets. It is well placed to put the setbacks of 2018 behind it and return to strong performance in future years.

ATTEMPTED ACQUISITION OF TODD RESEARCH LTD

The acquisition of Todd Research Limited had been a part of the Group's strategy for some time prior to FY 2018. The deal offered both technical and market synergies and Todd Research's recurring service revenue and overall margins made a very attractive acquisition target. Having agreed a transaction price with the vendor, the Board felt that the final deal structure, which included 6,250,000 shares issued at 4p and £2.0m of vendor loans, provided a viable and balanced way to finance this deal and minimised the dilution of existing shareholdings.

It was disappointing that, despite extensive face to face communication with Rise Step International Development Limited, the Group's largest shareholder, we were unable to achieve a positive vote for the resolutions required to complete the acquisition, In a further meeting, following the adjourned AGM, Rise Step made it clear that, while supporting the overall acquisition strategy, they remained opposed to the issuing of shares at the price achieved in the fund raising. The Board had the overwhelming support of other shareholders.

Legal and other costs totalling £250k were incurred.

FINANCIAL RESULTS

Sales declined to £3.5m (2017: £5.0m), impacted both by the cancelled order and lower security system sales in the Indian subcontinent. Gross margins were strong at 47% (2017: 38%) reflecting the change in the sales mix. Overheads (excluding the transaction costs relating to the failed acquisition of Todd Research) were fractionally higher at £1.6m (2017: £1.5m) and included a planned £100k increase in Research and Development spend. Profit before tax and exceptional costs was £96k (2017: £477k).

Taking into account legal and other costs related to Todd Research of £250k, the pre-tax loss, after this exceptional expenditure, was £154k.

The financial position of the Group is strong with net assets of £1.6m (2017: £1.8m) at the year end which includes a cash balance of £780k (2017: £1.3m) and has therefore been able to meet its working capital requirements throughout the year under review

The Group's stock includes portable systems in Work in Progress, manufactured in anticipation of new orders. This will allow a rapid response as they are received early in the new financial year.

BUSINESS REVIEW

Sales for portable X-ray systems declined over the prior year, having been impacted by the cancellation of a substantial order from an important Asian customer and by a lower volume of sales in other markets. However, important new customers were gained in a number of markets, including a first order in Brazil. An extensive marketing campaign with our distribution partners has developed a strong pipeline of opportunities.

In a project part funded by the UK Government's Innovate UK, the Group has developed new technology for its portable X-ray detectors with a view to enhancing the precision of the images produced. The aim is to allow our products to compete more directly with companies using the alternative, and more expensive, medical X-ray type detectors. Technology from this programme has now been incorporated in a new range of Detector systems called ThreatScan®2 which offers a four times increase in image resolution. The effect is equivalent to replacing a 1 megapixel camera with a 4 megapixel camera. The company now offers an even more distinct combination of price and performance to the portable X-ray market.

The Group delivered a record number of industrial x-ray systems during the year and has already received orders for two further systems in FY 2019. Particularly gratifying has been the acceleration in the roll out of our inspection systems by another major player in the emission controls industry. This customer has held a small number of units for some years but during FY 2018 deployed systems into European and Asian manufacturing plants. We maintain very close relationships with the key customers in this industry, an activity managed directly by our Sales Director, Vince Deery.

OPERATIONAL IMPROVEMENTS

At the start of FY 2018, the Group upgraded its internal processes to be compliant with the latest (2015) version of the ISO 9001 requirements for Quality Management Systems. The new processes were independently audited in November 2018 and subject to final confirmation has been re-certificated for a further three years. Significantly upgraded processes included those for new product development and the handling of defect reports. These are now part of a Continuous Improvement process designed to drive the Group's quality performance and enhance customer satisfaction.

A new Operations Manager has taken charge of research and development in addition to manufacturing and quality. An integrated approach to these important parts of the business should allow the business to better manage resources and the delivery of quality product to our security and industrial customers. 

OUR STRATEGY

Our strategy has been to build the Group using a combination of both organic and acquisition growth. Having failed to complete the acquisition of Todd Research, it is the Board's intention to focus on organic growth over the short term, with a view to recovering the Group's sales and profit performance to the levels achieved in FY 2017. Steps are already in place to achieve this: new sales and operations staff have been appointed and the product development programme is being redirected to add additional sources of revenue from the development of a new product range. Whilst at its earliest stages, the planned development will make use of existing Image Scan technologies and routes to market, minimising both product development time and the time required to develop new sales.

 

We target continued growth of the industrial business as our key customers further roll out our MDXi 400 X-ray screening systems into their global manufacturing operations. We plan to explore a number of opportunities to further extend this activity through adding new customers and applications and adding new functionality to our screening systems.

 

Our ambition to further grow the business through selectively targeted acquisitions remains, but the Board recognises that the value of the Group's performance will have to recover some recently lost ground before an equity fund raise becomes attractive to either current shareholders or potential investors.

 

OUTLOOK

We do not believe that the decline in sales of portable X-ray systems in FY 2018 is symptomatic of any wider decline in this market. There is a robust pipeline of opportunities for sales of such systems to police, military and para military users across the world and an order for 20 portable units has been received in the first months of the financial year.

 

We believe our technology is well differentiated in both price and performance, and that the significant enhancements made to the range of options and accessories available, make our system desirable in a wide range of markets and applications. Our recent sales manager hire will allow us to refocus our marketing efforts in Europe and South America to supplement our well-established positions in Asia, the Indian Subcontinent and the Middle East.

 

The sale of a record number of industrial screening systems in the last 12 months reflects the continued strength of the market for catalytic filters and diesel particulate filters, driven in part by tighter emissions control legislation in China. This demand flows through to our major customers in the supply chain for these devices and drives them to add, enhance or move capacity to reflect the new demand and this, in turn has led to them ordering and installing more inspection systems. While demand does naturally fluctuate year on year, we see it as a strong area for the Group with continuing strong margins from both equipment sales and aftermarket service and support. We look to continue to expand our customer base in this market and broaden the range of applications for our systems.

 

In the longer term, the Board continues to believe that a blend of organic and acquisition growth is the best way to deliver shareholder value, the greater scale providing both protection from market shocks and stronger amortisation of the relatively high fixed costs associated with a stock market listing.

 

BOARD CHANGE

Sarah Atwell King has been appointed to the board as Financial Director, having been Financial Controller since 2014. She retains her role as Company Secretary. Sarah brings considerable organisational and management strength to the Board.

STAFF

The Board values greatly the considerable efforts made by our staff and, on behalf of the Directors, I would like to take this opportunity to personally thank staff and shareholders for their continued commitment to Image Scan.

 

William Mawer

CHAIRMAN

5 December 2018

 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Note

2018

£

2017

£

 

 

 

REVENUE

3,464,910

5,033,636

 

Cost of sales

(1,819,617)

(3,104,007)

 

 

 

 

Gross profit

1,645,293

1,929,629

 

 

Other operating income

47,628

57,166

 

 

Operating expenses

Research and development expenses

(1,213,842)

(383,187)

(1,218,111)

(291,593)

 

 

 

 

Total administrative expenses

(1,597,029)

(1,509,704)

 

 

 

 

OPERATING PROFIT BEFORE EXCEPTIONAL COSTS

 

 

 

95,892

 

477,091

 

 

Exceptional costs

(250,458)

-

 

 

 

 

 

 

 

 

OPERATING (LOSS)/PROFIT

(154,566)

477,091

 

 

Finance income

344

286

 

 

 

 

(LOSS)/PROFIT BEFORE TAXATION

(154,222)

477,377

 

 

Taxation

(65,467)

102,811

 

 

 

 

(LOSS)/ PROFIT AND TOTAL COMPREHENSIVE INCOME FOR THE YEAR FROM CONTINUING OPERATIONS ATTRIBUTABLE TO THE EQUITY OWNERS OF THE PARENT COMPANY

 

 

 

(219,689)

 

580,188

 

 

 

 

 

 

Pence

Pence

 

Earnings per share

 

 

 

Basic

3

(0.16)

0.45

 

Diluted

(0.16)

0.43

 

 

 

 

 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

Note

2018

£

2017

£

NON-CURRENT ASSETS

Property, plant and equipment

33,944

26,842

Deferred Tax Asset

37,344

102,811

 

 

71,288

 

129,653

 

CURRENT ASSETS

Inventories

938,639

1,094,879

Trade and other receivables

783,470

1,557,678

Cash and cash equivalents

781,635

1,253,114

 

 

2,503,744

3,905,671

 

 

TOTAL ASSETS

2,575,032

4,035,324

 

 

CURRENT LIABILITIES

Trade and other payables

909,966

2,166,248

Warranty provision

34,999

47,977

 

 

944,965

2,214,225

 

 

NET ASSETS

1,630,067

1,821,099

 

 

EQUITY

Share capital

1,363,546

1,357,046

Share premium account

8,327,910

8,317,410

Retained earnings

(8,061,389)

(7,853,357)

 

 

TOTAL EQUITY ATTRIBUTABLE TO SHAREHOLDERS

1,630,067

 

1,821,099

 

 

 

 

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Share capital

£

Share premium

£

Retained earnings

£

 

Total

£

As at 1 October 2016

1,256,046

7,934,528

(8,450,523)

740,051

Profit for the year and total comprehensive income/(expenditure) for the year

-

-

580,188

580,188

Transactions with owners:

Shares issued during the year

101,000

426,000

-

527,000

Share issue Costs

-

(43,118)

(43,118)

Share-based transactions

-

-

16,978

16,978

 

 

 

 

As at 30 September 2017

1,357,046

8,317,410

(7,853,357)

1,821,099

Loss for the year and total comprehensive income/(expenditure) for the year

-

-

(219,689)

(219,689)

Transactions with owners:

Shares issued during the year

6,500

10,500

-

17,000

Share issue Costs

-

-

-

-

Share-based transactions

-

-

11,657

11,657

 

 

 

 

As at 30 September 2018

1,363,546

8,327,910

(8,061,389)

1,630,067

 

 

 

 

 

CONSOLIDATED CASH FLOW STATEMENT

Note

2018

£

2017

£

 

Cash flows from operating activities

 

Operating profit before research and development expenditure and exceptional costs

479,079

768,684

 

Research and development expenditure

(383,187)

(291,593)

 

Exceptional costs

(250,458)

-

 

 

 

 

Operating (loss)/profit

(154,566)

477,091

 

Adjustments for:

 

Depreciation

15,844

12,975

 

Impairment of inventories

43,602

30,116

 

(Increase)/decrease in inventories

112,638

(620,411)

(Decrease)/increase in trade and other receivables

744,208

(715,301)

 

(Decrease)/increase in trade and other payables

(1,256,282)

539,186

 

Decrease in warranty provisions

(12,978)

(3,255)

 

Share-based payments

11,657

16,978

 

 

 

 

Cash generated used in operating activities

(465,877)

(262,621)

 

Corporation tax recovered

-

-

 

 

 

 

Net cash flows used in from operating activities

(465,877)

(262,621)

 

 

 

 

Cash flows from investing activities

 

Interest received

344

286

 

Purchase of property, plant and equipment

(22,946)

(23,021)

 

 

 

 

Net cash used in investing activities

(22,602)

 (22,735)

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

Proceeds from issue of share capital

17,000

527,000

 

Financial costs of fundraising

-

(43,118)

 

 

 

 

Net cash generated from financing activities

17,000

483,882

 

 

 

 

 

Net (DECREASE)/INCREASE in cash and cash equivalents

(471,479)

198,526

 

Cash and cash equivalents at beginning of year

1,253,114

1,054,588

 

 

 

 

Cash and cash equivalents at end of year

781,635

1,253,114

 

 

 

 

 

Notes to the preliminary statement1. Basis of preparationThe financial information set out above does not constitute the Company's statutory accounts for the years ended 30 September 2018 and 30 September 2017 but is derived from those accounts. Statutory accounts for 2017 have been delivered to the Registrar of Companies, and those for 2018 will be delivered following the Company's Annual General Meeting. The auditors have reported on those accounts; their reports were unqualified and did not contain statements under Section 498 of the Companies Act 2006.

2. IFRS 2 'Share-based payments'Operating expenses includes a charge of £11,657 (2017: £16,978) after valuation of the Company's employee share options schemes in accordance with IFRS 2 'Share-based payments'. Under this standard, the fair value of the options at the grant date is spread over the vesting period. These items have been added back in the statement of changes in equity.

3. Earnings per share

Diluted profit per share is calculated by adjusting the weighted average number of ordinary shares in issue on the assumption of conversion of dilutive potential ordinary shares. The Company's dilutive potential ordinary shares are shares issued under the Company's Enterprise Management Incentive (EMI) scheme and options issued under the Company's Unapproved scheme.

 

2018

£

2017

£

 

 

(Loss)/profit for the year

(219,689)

580,188

 

 

 

 

Weighted average number of ordinary shares in issue

135,774,838

129,512,227

Number of diluted shares

141,207,627

135,165,601

 

 

 

Basic (loss)/ profit per share

(0.16p)

0.45p

 

Diluted (loss)/ profit per share

(0.16p)

0.43p

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FR FSUFWLFASEIE
Date   Source Headline
12th Mar 20247:00 amRNSLaunch of AXIS-CXi Cabinet with AI Software
28th Feb 20242:48 pmRNSResult of AGM
28th Feb 20247:00 amRNSTrading Statement
26th Jan 20241:50 pmRNSHolding(s) in Company
18th Jan 20241:28 pmRNSHolding(s) in Company
11th Jan 20243:06 pmRNSHolding(s) in Company
9th Jan 202412:46 pmRNSNotice of AGM & Posting of Annual Report
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company
12th Dec 20237:00 amRNSFinal Results
10th Oct 20237:00 amRNSTrading Update
11th Sep 20237:00 amRNS2023 orders to over 30 countries
4th Jul 20237:00 amRNSHolding(s) in Company
26th Apr 20237:00 amRNSInterim Results
13th Mar 20239:34 amRNSHolding(s) in Company
28th Feb 20233:03 pmRNSResult of AGM
28th Feb 20237:00 amRNSTrading Statement
10th Feb 20231:26 pmRNSHolding(s) in Company
26th Jan 202312:09 pmRNSDirector/PDMR Shareholding
18th Jan 20238:52 amRNSPosting of annual report and notice of AGM
17th Jan 20233:23 pmRNSImage Scan makes first sale of new product
23rd Dec 202211:54 amRNSDirector/PDMR Shareholding
14th Dec 20224:14 pmRNSAppointment of Director
13th Dec 20224:25 pmRNSHolding(s) in Company
13th Dec 20227:00 amRNSFinal Results
9th Dec 20227:00 amRNSNotice of Results
6th Oct 20227:00 amRNSTrading Update
1st Aug 20224:10 pmRNSHolding(s) in Company
25th May 20227:00 amRNSBoard Changes
27th Apr 20227:00 amRNSInterim Results
3rd Mar 20227:00 amRNSNew Industrial Customer
22nd Feb 20223:03 pmRNSResult of AGM
22nd Feb 20227:00 amRNSTrading Statement
20th Jan 202211:53 amRNSPosting of Accounts & AGM Notice
12th Jan 20227:00 amRNSLaunch of new portable X-ray system
10th Dec 20219:05 amRNSInvestor Presentation
7th Dec 202110:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
7th Dec 20217:00 amRNSFinal Results
10th Nov 20211:16 pmRNSAppointed global distributor for Serstech AB
10th Nov 20217:00 amRNSPortable x-ray sale to US Federal Agency
3rd Nov 20217:00 amRNSPre-Close Trading Update
27th Oct 20219:32 amRNSDirector Declaration
13th Sep 20217:00 amRNSTrading Update – New Orders
17th Jun 20217:00 amRNSFirst portable X-Ray sale to Australia
28th Apr 202110:03 amRNSInterim Report - Replacement
28th Apr 20217:00 amRNSNew order
28th Apr 20217:00 amRNSInterim Report
23rd Feb 202111:18 amRNSResult of AGM
22nd Feb 20217:00 amRNSTrading Statement
15th Feb 202111:33 amRNSMello presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.